Having trouble viewing this email? View it in your browser . Lire la version française

ASCO 2024 Edition: June 1-3
From June 1-4 2024, follow us on our LinkedIn or Facebook page for LIVE updates and daily interviews from the 2024 ASCO Annual Meeting (American Society of Clinical Oncology).  
All programs
Day 1
ASCO 2024: Daily RECAP
Daily recap, June 1st
Daily Review from ASCO 2024 with Dr. Jamil Asselah and Dr. Kim Ma.
Join Drs. Asselah and Ma as they review the key takeaways from Day 1 of ASCO. They delve into hormone-positive disease, discuss notable abstracts, and provide insights on the Flex trial registry. Hear about Dr. Grace Choong's research from Mayo Clinic on endocrine therapy for ER-low breast cancer patients.
June 1 2024
ASCO 2024: Global Speaker Series
Global speaker with Dr. Santa Maria
Join Dr. Santa Maria as he discusses his current project exploring the use of chemotherapy combined with immunotherapy in patients with stage 2 and 3 triple-negative breast cancer. Learn how early PET scan changes are being used to identify patients who achieve a complete pathologic response earlier in the treatment process.
June 1 2024
ASCO 2024: Global Speaker Series
Join Dr. Pier Franco Conte as he discusses the A-BRAVE trial, a Phase III randomized study exploring the use of avelumab in early triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy or those at high risk following primary surgery and adjuvant chemotherapy.
June 1 2024
ASCO 2024: Global Speaker Series
Watch Dr. Carlos A. Gonzalez Nuñez discuss 'De-escalation studies: The Next Step in Early Breast Cancer' in this brief video from the ASCO Meeting.
June 1 2024
Day 2
ASCO 2024: Daily RECAP
Daily recap, June 2nd
Join Dr. Jamil Asselah and Dr. Kim Ma, along with Dr. Véronique Diéras, as they review the day's highlights with a special focus on the positive findings from the DESTINY-Breast06 trial. They will discuss how these results are set to impact clinical practice, particularly for patients with HER2-ultralow breast cancer, and delve into all aspects of T-DXd in treatment strategies.
June 2 2024
ASCO 2024: MedTalk
Join Dr. Mark Basik as he presents the results of the TRICIA study, conducted across cancer centers and hospitals in Quebec and Ontario. Learn about the significant findings and the plans to initiate a clinical trial in the coming years, with the goal of advancing treatment options for this challenging type of cancer.
June 2 2024
ASCO 2024: Global Speaker Series
Join Dr. Nagi S. El Saghir as he discusses new studies presented at ASCO 2024. He highlights recent studies on the sequencing of CDK4/6 inhibitors and endocrine therapy in patients with advanced breast cancer.
June 2 2024
ASCO 2024: MedTalk
Join Dr. Jean-Pierre Ayoub as he reviews important results from the DESTINY-Breast06 trial. Learn how Trastuzumab Deruxtecan significantly improves progression-free survival in breast cancer patients previously treated with endocrine therapy. Discover the potential implications of these findings for patient care and treatment strategies.
June 2 2024
ASCO 2024: Global Speaker Series
Join Dr. Matthew P. Goetz as he discusses the open-label, randomized, multicenter phase 3 ELAINE 3 study. This research investigates the efficacy and safety of lasofoxifene combined with abemaciclib for treating ER+/HER2- locally advanced or metastatic breast cancer with an ESR1 mutation. Discover the potential impact of these findings on patient care and treatment options.
June 2 2024
ASCO 2024: Global Speaker Series
Join Dr. Jane Lowe Meisel as she presents the first results from the I-SPY2.2 trial at ASCO. This study explores the use of datopotamab deruxtecan as part of neoadjuvant therapy for high-risk, HER2-negative early-stage breast cancer.
June 2 2024
Day 3
ASCO 2024: MedTalk
Join Dr. Stephanie Wong at ASCO as she presents data on PARP inhibitor eligibility in women with newly diagnosed invasive breast cancer. This research is part of the GREAT AGATA Study, a universal genetic testing initiative aimed at improving patient outcomes.
June 3 2024
ASCO 2024: Global Speaker Series
Dr. Maryellen Giger discusses the exciting developments in artificial intelligence (AI) applied to breast cancer imaging. From risk assessment to early detection, diagnosis, prognosis, and treatment response, AI is making significant strides.
June 3 2024
ASCO 2024: Global Speaker Series
Dr. Shaheena Dawood shares her excitement about the wealth of information related to patients with breast cancer and how this data will impact clinical practice. In particular, she highlights three crucial pieces of information from ASCO and reviews data from the DESTINY-Breast06 Update, postMONARCH study and updated analysis from the innovaTV207 trial.
June 3 2024
ASCO 2024: Global Speaker Series
Dr. Judy-Anne Williams Chapman, PhD, emphasizes her four decades of work on the critical topic of estrogen and progesterone receptors. She proposes an adjunctive statistical standardization of quantitated ER and PgR to enhance inter-laboratory comparability of biomarker results and improve the therapeutic management of breast cancer.
June 3 2024
ASCO 2024: Global Speaker Series
Dr. Laura Dominici Chairs ASCO's "Breast Cancer Local/Regional/Adjuvant" therapy session where 9 abstracts covered a number of different topics, three of which look at some interesting additions to standard therapy.
June 3 2024
ASCO 2024: Global Speaker Series
Explore the findings of the PALMARES-2 study with Dr. Claudio Vernieri, offering crucial real-world insights into the efficacy of CDK4/6 inhibitors. Learn how these insights aid clinicians and patients in making informed treatment decisions for specific clinical settings.
June 3 2024


To view more precision medicine breast cancer news, editorial and educational programs Register now

 
Visit us on the web at oncoxchange.org - Contact Us?
This newsletter is distributed by oncoXchange.org, the Precision Medicine Breast Cancer platform.
oncoXchange.org is owned and operated by MedcomXchange.
Head office: 1196, rue Sherbrooke Ouest, Montréal (QC) H3A 1R6 CANADA